Trial Profile
Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NABUCCO
- 01 Mar 2023 Results assessing High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer published in the Nature Medicine
- 08 Feb 2023 Results published in the NeoGenomics Media Release.
- 31 Oct 2022 Results of a subset of patients in the NABUCCO-trial (NCT03387761) received ipilimumab plus nivolumab for locally advanced urothelial cancer published in the International Journal of Cancer